同步与连续免疫疗法与化学放射疗法用于不可切除的第三阶段非小细胞肺癌:一项回顾性研究
Zhou Meng-Xi1, Fan Wen-Jie1, Zhang Ning1
1Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Frontiers in oncology
|January 22, 2025
概括
与化学辐射疗法同时进行的免疫疗法在第三阶段非小细胞肺癌 (NSCLC) 治疗中,与连续给予相比,具有更好的疗效. 这种方法显示了改善的无进展生存率和总生存率,具有可管理的安全概况.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 第三阶段非小细胞肺癌 (NSCLC) 治疗通常涉及化疗放射治疗.
- 在NSCLC中,将免疫检查点抑制剂 (ICI) 与化疗放射治疗相结合的最佳时间尚未确定.
- 将免疫疗法与化疗放射治疗结合起来,对晚期的NSCLC显示出有前途.
研究的目的:
- 为了比较ICI与化学辐射疗法的并发与连续使用的疗效和安全性.
- 为了评估生存结果,包括无进展生存 (PFS) 和总生存 (OS),在患有不可切除的III期NSCLC的患者中.
- 评估与不同ICI计时策略相关的与治疗相关的不良事件.
主要方法:
- 对98名无法切除的第三期NSCLC患者的回顾性分析.
- 患者被分为相应或顺序ICI组相对于化疗或放射治疗.
- 评估的结果包括中位数PFS,中位数OS,PFS/OS率,客观缓解率 (ORR),疾病控制率 (DCR) 和不良事件.
主要成果:
- 同时ICI给药显示PFS中位数显著更长 (19.0 vs. 12.8个月,P=0.047) 和较高的1年和2年PFS比率相比顺序.
- 同时组显示了较高的2年和3年OS率.
- 远程转移在同时治疗组的频率较低 (13.8%与25.5%,P=0.049).
- 肺炎和血液毒性在各组之间是可比的,严重事件的可控率.
结论:
- 与化学放射疗法同时进行的免疫疗法优于对不可切除的III期NSCLC进行连续的治疗.
- 这种并发方法提供了更好的生存效益,并证明了良好的安全性和耐受性.
- ECOG性能状态和瘤分化是PFS和OS的独立预后因素.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.4K
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.2K
相关概念视频
01:27Tumor Immunotherapy
467
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
467
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K